Equities research analysts expect that MorphoSys AG Unsponsored ADR (NYSE:MOR) will report earnings of ($0.38) per share for the current fiscal quarter, Zacks Investment Research reports. Two analysts have made estimates for MorphoSys’ earnings, with estimates ranging from ($0.42) to ($0.33). MorphoSys posted earnings of ($0.39) per share during the same quarter last year, which suggests a positive year-over-year growth rate of 2.6%. The company is scheduled to announce its next quarterly earnings results on Wednesday, March 11th.

On average, analysts expect that MorphoSys will report full year earnings of ($0.90) per share for the current financial year, with EPS estimates ranging from ($0.98) to ($0.82). For the next fiscal year, analysts anticipate that the business will post earnings of ($1.15) per share, with EPS estimates ranging from ($1.37) to ($0.80). Zacks’ earnings per share averages are an average based on a survey of sell-side analysts that that provide coverage for MorphoSys.

Shares of MOR opened at $31.54 on Friday. MorphoSys has a fifty-two week low of $22.46 and a fifty-two week high of $31.96. The stock has a fifty day moving average of $28.08 and a two-hundred day moving average of $27.52.

MorphoSys Company Profile

MorphoSys AG, together with its subsidiaries, engages in the research, development, and optimization of therapeutic antibody drug candidates in partnership with pharmaceutical and biotechnology companies. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 100 drugs for the treatment of cancer, Alzheimer's disease, infectious diseases, cardiovascular dysfunction, and inflammation.

Featured Article: How can investors benefit from after-hours trading?

Get a free copy of the Zacks research report on MorphoSys (MOR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for MorphoSys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys and related companies with MarketBeat.com's FREE daily email newsletter.